35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide

C. Faivre-Finn; P. Lorigan; F. Blackhall; L. Ashcroft; E. Lyn; M. Lee; R. McMenemin; N. Mohammed; A. Price; R. Stephens; M. Snee; J. VanMeerbeck; P. Woll

doi:10.1016/s0169-5002(07)70361-6

35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide

C. Faivre-Finn, P. Lorigan, F. Blackhall, L. Ashcroft, E. Lyn, M. Lee, R. McMenemin, N. Mohammed, A. Price, R. Stephens, M. Snee, J. VanMeerbeck, P. Woll

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S10
Journal	Lung Cancer
Volume	57
Issue number	Supplement 1
DOIs	https://doi.org/10.1016/s0169-5002(07)70361-6
Publication status	Published - Aug 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s0169-5002(07)70361-6

Cite this

Faivre-Finn, C., Lorigan, P., Blackhall, F., Ashcroft, L., Lyn, E., Lee, M., McMenemin, R., Mohammed, N., Price, A., Stephens, R., Snee, M., VanMeerbeck, J., & Woll, P. (2007). 35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide. Lung Cancer, 57(Supplement 1), S10. https://doi.org/10.1016/s0169-5002(07)70361-6

Faivre-Finn, C. ; Lorigan, P. ; Blackhall, F. et al. / 35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide. In: Lung Cancer. 2007 ; Vol. 57, No. Supplement 1. pp. S10.

@article{1ae082ce55aa4612bd64e805d9722f3e,

title = "35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide",

author = "C. Faivre-Finn and P. Lorigan and F. Blackhall and L. Ashcroft and E. Lyn and M. Lee and R. McMenemin and N. Mohammed and A. Price and R. Stephens and M. Snee and J. VanMeerbeck and P. Woll",

year = "2007",

month = aug,

doi = "10.1016/s0169-5002(07)70361-6",

language = "English",

volume = "57",

pages = "S10",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier BV",

number = "Supplement 1",

}

Faivre-Finn, C , Lorigan, P , Blackhall, F, Ashcroft, L, Lyn, E, Lee, M, McMenemin, R, Mohammed, N, Price, A, Stephens, R, Snee, M, VanMeerbeck, J & Woll, P 2007, '35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide', Lung Cancer, vol. 57, no. Supplement 1, pp. S10. https://doi.org/10.1016/s0169-5002(07)70361-6

35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide. / Faivre-Finn, C.; Lorigan, P.; Blackhall, F. et al.
In: Lung Cancer, Vol. 57, No. Supplement 1, 08.2007, p. S10.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - 35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide

AU - Faivre-Finn, C.

AU - Lorigan, P.

AU - Blackhall, F.

AU - Ashcroft, L.

AU - Lyn, E.

AU - Lee, M.

AU - McMenemin, R.

AU - Mohammed, N.

AU - Price, A.

AU - Stephens, R.

AU - Snee, M.

AU - VanMeerbeck, J.

AU - Woll, P.

PY - 2007/8

Y1 - 2007/8

UR - http://www.mendeley.com/research/35-converta-multicentre-randomised-controlled-ncrn-trial-comparing-accelerated-twicedaily-high-dose

U2 - 10.1016/s0169-5002(07)70361-6

DO - 10.1016/s0169-5002(07)70361-6

M3 - Article

SN - 0169-5002

VL - 57

SP - S10

JO - Lung Cancer

JF - Lung Cancer

IS - Supplement 1

ER -

Faivre-Finn C , Lorigan P , Blackhall F, Ashcroft L, Lyn E, Lee M et al. 35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide. Lung Cancer. 2007 Aug;57(Supplement 1):S10. doi: 10.1016/s0169-5002(07)70361-6

35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide

UN SDGs

Access to Document

Other files and links

Cite this